MPR1d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
Soleno Therapeutics (SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone with FDA approval ...
Pharmaceutical Technology on MSN5d
Soleno wins FDA approval for Prader-Willi hyperphagia treatment
Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...
PharmExec5d
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome
Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.
BioPharma Dive6d
First Prader-Willi drug to reduce hunger approved by FDA
Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.
Explore more
Investor's Business Daily on MSN5d
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
Managed Healthcare Executive5d
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...
Tiny Silicon Valley drugmaker soars on FDA win to treat never-ending hunger
Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...
STAT5d
NIH director targets misinformation research as more turmoil rocks health agencies
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome
The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, ...